Skip to main content
Top
Published in: Reactions Weekly 1/2022

01-06-2022 | Sweet's Syndrome | Case report

Ivosidenib

Differentiation syndrome: case report

Published in: Reactions Weekly | Issue 1/2022

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Tabata MM, et al. Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation. Journal of Cutaneous Pathology 47: 1042-1045, No. 11, Nov 2020. Available from: URL: http://doi.org/10.1111/cup.13780 Tabata MM, et al. Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation. Journal of Cutaneous Pathology 47: 1042-1045, No. 11, Nov 2020. Available from: URL: http://​doi.​org/​10.​1111/​cup.​13780
Metadata
Title
Ivosidenib
Differentiation syndrome: case report
Publication date
01-06-2022
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-17962-7

Other articles of this Issue 1/2022

Reactions Weekly 1/2022 Go to the issue

Case report

Multiple drugs

Case report

Beraprost

Case report

Bedaquiline